Therapeutic Area Partnerships Features Next Generation of Oncology
New Wave of Newer Classes Will Be Discussed by Experts at Campbell
BRIDGEWATER, NJ -- (Marketwire) -- 11/19/12 -- Next week Elsevier
Business Intelligence will host the 7th Annual Therapeutic Area
Partnerships (TAP) at The Westin Copley Place in Boston on Nov.
28-30, 2012. TAP is the most efficient partnering meeting for
biopharmaceutical companies and executives seeking to understand,
within their therapeutic area portfolio, the strategic outlook for
new products in development, alliance opportunities, and current
industry pipeline needs and future projections.
One of the six therapeutic areas featured at the conference, oncology
remains by far the largest and most active deal-making space in the
biopharmaceutical industry. While many new drugs will reach the
market in the next few years, existing blockbusters and other widely
used agents will soon go generic, potentially impacting reimbursement
and uptake for novel medications. Emerging diagnostic biomarkers,
immunotherapies and conjugated biological therapies have the
potential to transform the way patients are treated. The
fast-changing oncology landscape and its implications for the
industry will be the subject of a roundtable of oncology business
development leaders from four major global pharmaceutical firms
guided by an expert team from Campbell Alliance, an industry leader
in biopharmaceutical and medical technology consulting and part of
The oncology-specific segments of TAP include a panel discussion and
presentation of the Top Projects to Watch. The panel, including
executives from AstraZeneca, Genentech, EMD Serono and Sanofi, will
give attendees actionable intelligence on the trends, hurdles and
opportunities that will shape the future of oncology drug
development, alliances, and commercialization.
The Top Projects to Watch in oncology were hand-picked by the
Campbell Alliance team based on their likelihood of success as future
products. The companies confirmed to present their oncology projects
this year are:
Apogenix GmbH: (Apocept) APG101
BIND Biosciences: BIND-014
Jennerex Biotherapeutics: JX-929
Pharmaceuticals, Inc.: KB004
EnGeneIC: EDV technology
Shape Pharmaceuticals: SHP 141
"The next decade in oncology will see newer classes of agents added
to the treatment armamentarium," said Guru Muralimohan, engagement
manager at Campbell Alliance. "Cytotoxics will become smarter and
more targeted. Immunotherapies will produce a new wave of
blockbusters as they leverage the human body's own immune system to
help combat cancer. And, next generation agents targeting cancer cell
metabolism will have the potential for disruptive change in the
oncology treatment paradigm."
"These ten assets represent the leading edge of this sea change in
oncology, and were chosen through an exhaustive process that took
into account a variety of factors," added Jonathan Betts, Engagement
Manager at Campbell Alliance. Such factors included what key opinion
leaders have defined as the most promising mechanistic approaches and
emerging trends based on Campbell Alliance's 2012 Dealmakers'
Intentions Survey as well as the firm's understanding of areas of
high current licensing activity within oncology and knowledge gained
through assisting multiple companies develop oncology strategies.
Both Muralimohan and Betts will co-present the oncology Top Projects
TAP is a one-of-a-kind opportunity to assess some of the most
promising drugs in development and available for partnering in
Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious
Diseases, Autoimmune/Anti-Inflammatory Diseases, and Hot Space.
Attracting the highest concentration of senior-level biotechnology
and pharmaceuticals executives, TAP has come to be regarded as one
the most productive, results-oriented deal-making conferences in the
industry. For more information, or to register for this event, visit
About Elsevier Business Intelligence
Elsevier Business Intelligence,
a global leader in the field of healthcare industry information,
provides business intelligence on regulatory, business and
reimbursement issues that are vital to the healthcare industry.
Through a range of products including publications, conferences,
e-learning, databases and reports, Elsevier Business Intelligence
places biopharma and medical device professionals, and those who
focus on these industries, at the forefront of knowledge, by
providing the perfect combination of news and information together
with penetrating insight and analysis. Our leading publications
include PharmAsia News, IN VIVO and "The Pink Sheet." For more
information, visit: http://www.ElsevierBi.com.
Elsevier is a world-leading provider of scientific,
technical and medical information products and services. The company
works in partnership with the global science and health communities
to publish more than 2,000 journals, including The Lancet and Cell,
and close to 20,000 book titles, including major reference works from
Mosby and Saunders. Elsevier's online solutions include SciVerse
ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's
Nursing Suite, which enhance the productivity of science and health
professionals, and the SciVal suite and MEDai's Pinpoint Review,
which help research and health care institutions deliver better
outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000
people worldwide. The company is part of Reed Elsevier Group PLC, a
world-leading publisher and information provider, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
Elsevier Business Intelligence
Press spacebar to pause and continue. Press esc to stop.